Work

Evaluating pegylated SN38 (PLX38A) and rucaparib in TP53 wild-type endometrial cancer.

Year: 2025

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e15125

Authors: Mikayla Brennan, Saravut John Weroha, Xiaonan Hou, Scott H. Kaufmann, Sean Christopher Dowdy, Gretchen Glaser, Conway Xu

Institution: Mayo Clinic

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410815580

FWCI:

Cites:

Cited by:

Related to: 10